Some investors asked on the investor interaction platform: has the company’s diabetes peptide drugs been listed?
Dezhan Healthcare Company Limited(000813) ( Dezhan Healthcare Company Limited(000813) . SZ) said on the investor interaction platform on April 25 that the company’s somaluptide and liraglutide products are in the process of research and development and have not yet been put on the market.
